Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 2, 2019 (8 years ago)

Cidofovir Injection 375mg/5mL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: complaints received about dried powder on the outside of bottle

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Cidofovir Injection 375mg/5mL (75mg/mL) vial injection. 5 mL vials, Rx only, Mfd by: Emcure Pharmaceuticals Ltd., Hinjawadi, Pune, India Mfg. for : Heritage Pharmaceuticals Inc. NDC 23155-0216-31

Affected NDC 23155-0216-31

Compare with the code on your package — it is the most precise check available.

Drug: Cidofovir

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cidofovir Dihydrate
NDC 23155-0216
CIDOFOVIR 375 mg/5mL Injection, Solution
Intravenous
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. Rx
Recalling firm
Heritage Pharmaceuticals, Inc.
NDC code
23155-0216-31
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0352-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cidofovir recalls

See all
Class II · Moderate risk

Cidofovir Dihydrate

CGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.

Terminated cGMP deviation LGM Pharma LLC D-0486-2019
Class II · Moderate risk

Cidofovir Dihydrate active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-584-2015
Class II · Moderate risk

Cidofovir Anhydrous active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-583-2015
Class II · Moderate risk

Cidofovir Opthalmic Solution

Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance

Terminated Sterility / contamination Pallimed Solutions D-863-2013

Other recalls by Heritage Pharmaceuticals, Inc.

All 2019 recalls
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-583-25 D-0112-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-582-01 D-0111-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-581-01 D-0110-2026